Literature DB >> 8501266

A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin.

J Price1, J O'Day.   

Abstract

In the neuro-ophthalmology clinic at St. Vincent's Hospital, Melbourne, 57 patients with blepharospasm and 50 patients with hemifacial spasm were treated with botulinum toxin. Schirmer tear tests were conducted on all the patients prior to each treatment and at 1 week following treatment where possible. The results were compared with a control group of 107 patients selected by age and sex. The blepharospasm patients were found to have a significantly lower tear secretion than that of the control group, using the Mann-Whitney test (median = 3.5 mm, compared with median-11.0 mm, p < .0001). This did not improve following treatment. The patients with hemifacial spasm did not have significantly different tear secretion from that of the control group (t = 1.0, p > .05). To investigate whether there was any relationship between the symptoms and the result of the Schirmer test, a survey was also conducted on the patients with blepharospasm and hemifacial spasm regarding symptoms, frequency, and type of drops/ointment used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501266

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  8 in total

1.  Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.

Authors:  J Horwath-Winter; J Bergloeff; I Floegel; E-M Haller-Schober; O Schmut
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.

Authors:  Yoshihiko Isshiki; Hiroto Ishikawa; Osamu Mimura
Journal:  Jpn J Ophthalmol       Date:  2016-08-08       Impact factor: 2.447

3.  Botulinum neurotoxin type A versus punctal plug insertion in the management of dry eye disease.

Authors:  Amal A Bukhari
Journal:  Oman J Ophthalmol       Date:  2014-05

4.  Comparison Between Botulinum Toxin A Injection and Lacrimal Punctal Plugs for the Control of Post-LASIK Dry Eye Manifestations: A Prospective Study.

Authors:  Sameh M Fouda; Hala K Mattout
Journal:  Ophthalmol Ther       Date:  2017-02-02

Review 5.  Application of botulinum toxin in maxillofacial field: Part II. Wrinkle, intraoral ulcer, and cranio-maxillofacial pain.

Authors:  Kyung-Hwan Kwon; Kyung Su Shin; Sung Hee Yeon; Dae Gun Kwon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2019-10-16

6.  Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.

Authors:  Marco Pellegrini; Costantino Schiavi; Leonardo Taroni; Stefano Sebastiani; Federico Bernabei; Matilde Roda; Fabiana Moscardelli; Giuseppe Giannaccare
Journal:  Indian J Ophthalmol       Date:  2019-09       Impact factor: 1.848

7.  Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A.

Authors:  Supharat Jariyakosol; Lita Uthaithammarat; Nattakarn Chatwichaikul; Ngamjit Kasetsuwan; Yuda Chongpison
Journal:  Clin Ophthalmol       Date:  2021-04-28

8.  In vivo confocal microscopy of meibomian glands in primary blepharospasm: A prospective case-control study in a Chinese population.

Authors:  Tong Lin; Lan Gong
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.